HAVN Life Is My Ground Floor Psychedelic Stock

Havn Life Sciences Inc.HAVN : CSE) is the psychedelic stock that has a huge first mover advantage, blue chip leadership group and superior business model.

Havn Life gives investors direct exposure to the exploding growth of psychedelic medicine. 

This is the sector that investors need to have exposure to and this is the single best company to own.

The excitement around this space is what sent shares of Compass Pathways (CMPS: NASDAQ) up more than 70% on its first day of trading just days ago.

The IPO was 4x oversubscribed with many dedicated life sciences and bio tech funds in the deal—showing how mainstream this sector has become so fast!  Compass now has a $1 billion+ valuation.

The management group behind Havn is proven—they have built up big companies and made shareholders wealthy.  These are the exact people that you want building a company that has this opportunity set in front of it.

You don’t need me to tell you this.  The track records of this group do the talking for me.

Havn’s Co-CEO is Tim Moore. 

As CEO of Green Growth Brands (GGB: CSE) Moore led the company from a micro-cap valuation at its IPO to a $1 billion market cap when he left the company in January 2019.

Moore knows how to push all of the right buttons to get the market to recognize value and get full value for his shareholders in a short amount of time.

 

 

Moore has a deep resume prior to Green Growth having been President of Clorox Canada, COO of Synnex Canada and Managing Director at Brita North America.  Those are big, big packaged goods businesses.

Joining Moore is key Director Vic Neufeld — a LEGEND of Canadian business.

I can’t stress this enough.  Neufeld is literally the exact man that you want attached to this company at this stage.  His involvement here is A Big Deal. 

Like CEO Moore, Neufeld has previously been CEO of a public market homerun. 

Under his 5 years as CEO, Neufeld built Aphria (APHA: Nasdaq) from nothing more than idea into one of the largest (near $4 billion market cap) and most successful cannabis producers in the world.   

Under Neufeld Aphria’s stock went from 75 cents to $22 in its first three years of trading — a nice little 30-bagger out of the gate. 

 

 

Success follows this man.

After earning an MBA in 1978 Neufeld became a chartered accountant where he shot up the ranks at accounting firm Clarkson Gordon—and at age 32 he became  youngest partner in history there..

But Neufeld is an entrepreneur at heart, so Neufeld left his cushy partner income behind and joined Jamieson Laboratories Ltd as CEO in 1993—when the company was valued at $20 million and had 98 employees with four executives.

What he built there was a dominant, global health brand.

Over 21 years, 98 employees became 600.  $20 million of revenue increased exponentially to $250 million. Market share increased from 7 percent to 27 per cent and countries of operation went from 4 to 44.

In 2014 Neufeld sold Jamieson to a private equity firm for $310 million — an increase in valuation of $290 million over two decades.  A private market 15-Bagger.

Under his watch Jamieson became Canada’s largest manufacturer and distributor of natural vitamins, minerals, concentrated food supplement.

As I said……exactly the man you want involved with Havn today. And Havn doesn’t just have Vic—Vic has also brought key members of his team—including Gary Leong, his former Chief Scientific Officer at Jamieson Laboratories.

 

Havn’s Two-Pronged Business Model

 

There are two parts to the Havn story and the company has a huge advantage in both.

This a business with two distinct arms.  The company is split into:

Havn Labs – the huge opportunity where psychedelics are used medically to treat all kinds of mental health issues.

Havn Retail – Which is targeting a non-medical, natural, mental wellness micro-dosing therapies that will be sold directly to the public.  In other words a wellness health brand exactly like Neufeld built at Jamieson.

 

 

I told you about the advantage that Havn Labs has on the medical psychedelic front yesterday.  Havn Labs is the only company with a  Section 56 exemption to work towards becoming a supplier controlled psychedelic compounds.

These exemptions have to date only been granted to Universities and other researchers or to individuals for, typically, end of life alternative treatments.

That puts Havn a mile ahead of the competition.  The competition isn’t even in the game yet!

The incredible success that psychedelic studies have seen with helping people with

  1. depression,
  2. PTSD,
  3. addiction and
  4. end of life anxiety

has spurred the next generation of studies.

More studies on psychedelics are being launched all the time.  Havn’s Moore told me more than 140 of these studies that are now going on worldwide.

What all of these studies need but don’t have is a natural source of psychedelics, specifically the psilocybin that is found in magic mushrooms.  As a controlled substance there simply is no supply. There is no existing supply chain of naturally derived psilocybin.

That means that as of today almost all of the studies being conducted are forced to use synthetic versions of the psychedelic.  The synthetic version is absurdly expensive and costs multiples more than the natural version.

With the only Section 56 exemption, HAVN has the inside track to becoming the supplier of choice for everyone in need.  Everyone using synthetic wants to have a natural source.  KA-CHING!!!!

Remember—psychedelics are a closely controlled substance.  While there are miraculous results coming from studies using them, this has to be done safely.   Government regulators will go slowly and carefully here.

There simply aren’t going to be many companies granted approval to do this.  Everyone is on the same page and wants a safe and reliable supply chain.  Once regulators governing the supply and institutions using it are comfortable with the source—it will be nearly impossible to displace the psychedelic supplier.

Havn wants to provide the psychedelic compounds that academic institutions require.  The company is already well on the way to that goal.  There is a huge, protective, competitive moat being built around this business.

The numbers involved here are huge.  An estimated 11% of the people in the world have some form of mental ailment.  That means that there is more than 700 million people who could benefit from psychedelics.

The growth curve here–and the stock market response—will be just like what we saw with cannabis during the initial boom. 

Havn Retail Creates
The Superior Business Model

Now, I could just end the story right there.  I think I’ve outlined an incredible team in a nascent industry that already has a head start.

And did I mention this company just got listed—that this is ground floor?

But there’s more.  I’ve already told you how, at Jamieson Labs, Vic Neufeld built one of the most successful retail health brands in history. 

Havn is leveraging Nuefeld’s knowledge and connections to do the same with a microdosing-focused-natural-health product that could help millions and millions of people.

Where psilocybin and psychedelic compounds are still controlled substances—other psychoactive compounds contained in mushrooms and other plants are not. 

These natural psychoactive compounds have also been use for many years to help people deal with anxiety, depression, panic attacks, OCD, anger management, sleep disorders and all kinds of other issues.

The plan for Havn Retail is to offer natural compounds for microdosing.

Microdosing is using a VERY small dose of a psychoactive compound that has a similar benefit to a full psychedelic–but allows the user have a normal day, go to work or whatever.

Havn’s microdosing compounds are regulated as natural health products  and will be sold directly to the consumer—who will take it on a daily basis. That means a RECURRING REVENUE stream for Havn.

This is the superior business model that Havn has.  The company has Vic Neufeld to help them build a revenue producing, cash flowing retail health brand.

It also has the connections of CEO Moore who was at Clorox for 18 years and North America Brita for another 7 years.  Moore has called on every major retailer in North America.  The Havn team is an elite group when it comes to knowing how to build a branded business and deal with major retails.

Other psychedelic stocks are one-trick ponies that will need constant new capital. Havn meanwhile should quickly become a cash flowing business.

Havn has the best possible team behind it and is selling into a rapidly growing demand for natural mushroom wellness products.

 

People are already self-medicating with mushrooms—first responders, veterans, front-line workers, stay at home moms.  The demand is there and Havn is going to build the brand name to supply them — just like Neufeld did at Jamieson Labs as demand for those wellness products increased.

What the Jamieson name is to vitamins—Havn aims to be that for its product niche.

There is a very clear vision at Havn and the company has built an all-star team that has proven that it can execute that vision better than anyone else.

Havn’s two pronged approach to building a self-sustaining cash flowing business makes it the psychedelic stock to own.

DISCLOSURE—I AM LONG HAVN LIFE SCIENCES

HAVN Life has reviewed and sponsored this article. The information in this newsletter does not constitute an offer to sell or a solicitation of an offer to buy any securities of a corporation or entity, including U.S. Traded Securities or U.S. Quoted Securities, in the United States or to U.S. Persons. Securities may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and applicable U.S. state securities laws or pursuant to an exemption therefrom. Any public offering of securities in the United States may only be made by means of a prospectus containing detailed information about the corporation or entity and its management as well as financial statements. No securities regulatory authority in the United States has either approved or disapproved of the contents of any newsletter.

 

Keith Schaefer is not registered with the United States Securities and Exchange Commission (the “SEC”): as a “broker-dealer” under the Exchange Act, as an “investment adviser” under the Investment Advisers Act of 1940, or in any other capacity. He is also not registered with any state securities commission or authority as a broker-dealer or investment advisor or in any other capacity.